/ 2 items

#TCRX↓

TCRX/ 09/02/2026 · 9:36 AM

TScan Pivots to In-Body T-Cell Therapy for Solid Tumors, Cuts 75% of Staff

TScan is shifting to in vivo TCR-T for solid tumors, pausing Phase 3 enrollment in TSC-101 and cutting about 75% of staff. Cash is expected to last into Q4 2027.

TCRX/ 11/03/2025 · 10:19 AM

TScan Therapeutics Pauses Solid Tumor Trial to Prioritize Heme, and Extends Cash Runway into Second Half of 2027

TScan Therapeutics (TCRX) announced a major strategic shift, securing FDA alignment for its pivotal TSC-101 trial for blood cancers, improving manufacturing speed, and cutting costs to extend its financial health into the second half of 2027.